Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Frost & Sullivan
Adoption of HIV nucleic acid testing and automation to spur market growth
LONDON, Feb. 20, 2013 /PRNewswire/ -- Over 32% of HIV+ people in Europe remain undiagnosed. This large untapped pool and the development of novel nucleic acid test (NAT) and non-NAT technology based platforms offers growth potential for HIV diagnostics manufacturers.
New analysis from Frost & Sullivan (http://www.healthcare.frost.com), Analysis of European HIV Diagnostics Market, finds that the market is estimated to expand from $797.1 million in 2012 to approximately $1,164.4 million in 2019. The research covers HIV NAT diagnostics and immunodiagnostics.
"Rising public awareness about HIV is boosting test volumes," notes Frost & Sullivan Senior Research Analyst K. Srinivas Sashidhar. "This has motivated the development of new products based on NAT and non-NAT technology platforms. The introduction of such innovative diagnostics products will be the key success factor in this market."
Heightened interest in companion diagnostics and the adoption of automation in laboratories will reinforce market growth.
"There is a significant need for highly sensitive HIV/AIDS assays in the market, which can detect very low levels of viral RNA copies," comments Sashidhar. "Companies are developing automated platforms to remain competitive."
In addition, there is a greater need to recognise the correlation between virus mutations and the efficacy of various antiretroviral therapies (ARTs). Companion diagnostics are a key solution to understanding this correlation.
"Viral genotyping is a popular trend to determine mutations in the HIV genome as they mostly lead to drug resistance," adds Sashidhar. "These demands will spur innovation, while driving market growth throughout the forecast period."
For a variety of reasons, the level of undiagnosed population in Europe remains quite high. The biggest challenge for market participants is thus to identify and tap into this segment.
Proper education and awareness will help boost test volumes and demand for HIV diagnostic kits. Effective, low-cost offerings, together with a wide range of services including periodic kit demonstrations, can advance market prospects.
If you are interested in more information on this study, please send an email with your contact details to Anna Zanchi, Corporate Communications, at email@example.com
Analysis of European HIV Diagnostics Market is part of the Life Sciences Growth Partnership Service programme. Frost & Sullivan's related research services include: European HIV/AIDS and Hepatitis B/C Molecular Diagnostics Market, Western European In Vitro Diagnostics (IVD) Market, CEE IVD Market, and European Point of Care Testing Market. All research included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
©2012 PR Newswire. All Rights Reserved.